Saturday 17 October 2026
Export OCUL’s income statement to Excel — free account
Ocular Therapeutix, Inc.
OCUL Healthcare Biotechnology
Ocular Therapeutix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $52.0 million, down 18.5% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 10.3%, free cash flow fell 25.4% and total debt rose 4.13%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.87
0.51
−6.91%
Follow OCUL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
42.44 | 36.48 | 43.75 | 38.54 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(32.84) | (28.76) | (41.90) | (42.39) | |
P/B ratio |
4.25 | 3.26 | 3.47 | 8.33 | |
Price to Tangible BV |
4.25 | 3.26 | 3.47 | 8.33 | |
EV/Sales |
32.34 | 25.05 | 30.94 | 33.63 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(7.07) | (5.76) | (7.85) | (9.87) | |
EV/FCF |
(6.60) | (5.41) | (7.42) | (9.41) | |
Quick Ratio |
12.79 | 14.49 | 15.11 | 7.62 | |
Current Ratio |
13.11 | 14.81 | 15.39 | 7.85 | |
Net Debt/EBITDA |
6.55 | 6.46 | 9.72 | 4.05 | |
Debt/Assets |
10.84% | 9.84% | 8.83% | 17.19% | |
Debt/Equity |
0.14 | 0.12 | 0.11 | 0.27 | |
Asset Turnover |
0.09 | 0.09 | 0.08 | 0.12 | |
Operating CF/Net income |
0.85 | 0.74 | 0.84 | 0.73 | |
Capex/Depreciation |
(1.82) | (3.63) | (2.28) | (5.61) | |
Interest Coverage |
(29.41) | (33.61) | (24.62) | (22.88) | |
Research and Development Expense of Revenue |
401.77% | 613.94% | 383.40% | 360.00% | |
Selling, General and Administrative Expense of Revenue |
292.65% | 339.20% | 231.07% | 200.15% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
108.71% | 144.48% | 85.73% | 80.38% | |
Graham Net Nets |
0.22 | 0.29 | 0.28 | 0.11 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(14.46%) | (17.24%) | (11.86%) | (12.32%) | |
Free Cash Flow Yield |
(11.55%) | (12.69%) | (9.54%) | (9.27%) | |
Revenue per Share |
0.06 | 0.05 | 0.07 | 0.08 | |
Operating CF per Share |
(0.30) | (0.29) | (0.29) | (0.28) | |
Capex per Share |
(0.01) | (0.02) | (0.02) | (0.03) | |
Free Cash Flow per Share |
(0.31) | (0.32) | (0.30) | (0.31) | |
Cash per Share |
2.66 | 2.98 | 3.94 | 1.87 | |
Shareholders Equity per Share |
2.31 | 2.60 | 3.49 | 1.40 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.31 | 2.60 | 3.49 | 1.40 | |
Free Cash Flow |
(70.64) | (70.65) | (57.09) | (56.72) | |
Working Capital |
595.25 | 658.31 | 731.32 | 337.69 | |
Capital Expenditures |
(3.37) | (4.66) | (2.84) | (5.99) | |
Net Current Asset Value |
493.15 | 555.04 | 628.38 | 234.33 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.25 | 0.43 | 0.21 | 0.41 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
30.34 | 24.78 | 31.52 | 30.50 | |
Average Payables |
6.44 | 6.33 | 4.17 | 5.13 | |
Average Inventory |
3.43 | 3.50 | 3.30 | 2.95 | |
Average Assets |
561.33 | 569.22 | 633.00 | 450.63 | |
Average Common Equity |
412.98 | 423.75 | 484.83 | 305.13 |
Columns are period end dates